EU Approves Tovorafenib for Pediatric Low-Grade Glioma with BRAF Alterations

Drug Approvals /

The European Commission has granted conditional approval to tovorafenib (Ojemda) for children aged 6 months and older with relapsed or refractory pediatric low-grade glioma (pLGG) carrying BRAF alterations. This is the first systemic therapy specifically approved in the EU for BRAF-rearranged pLGG. The decision is based on results from the FIREFLY-1 trial, where the drug […]

EU Approves Tovorafenib for Pediatric Low-Grade Glioma with BRAF Alterations Read More »

Tumor Structure Predicts Immunotherapy Success in Melanoma, Study Finds

Immunotherapy /

A study found that the physical arrangement of immune cells inside melanoma tumors plays a key role in determining whether immunotherapy works. Researchers analyzed tumor samples from patients in the SWOG S1616 clinical trial using advanced imaging and genetic tools. They discovered that patients who responded to treatment had active CD8 T cells clustered close

Tumor Structure Predicts Immunotherapy Success in Melanoma, Study Finds Read More »

Sac-TMT Shows Promising Activity in Advanced Urothelial Cancer After Prior Treatments

Treatment /

After Prior Treatments A phase 1/2 study (2870-001/KL264-01) reports that sacituzumab tirumotecan (sac-TMT), a TROP2-targeting antibody-drug conjugate, shows strong antitumor activity in patients with advanced or metastatic urothelial carcinoma who have already failed standard treatments. Among 49 heavily pretreated patients, the overall response rate was 31%, with higher responses (50%) in those who had only one

Sac-TMT Shows Promising Activity in Advanced Urothelial Cancer After Prior Treatments Read More »

More Daily Steps Can Offset Health Risks of Prolonged Sitting, Study Finds

Research Advances /

A study shows that increasing daily steps can reduce the health risks of prolonged sitting. Using data from more than 72,000 participants in the UK Biobank, researchers tracked activity and health outcomes over nearly seven years. They found the greatest benefits at 9,000–10,000 steps per day, lowering the risk of death by 39% and cardiovascular

More Daily Steps Can Offset Health Risks of Prolonged Sitting, Study Finds Read More »

mRNA-4359 Boosts Keytruda Response, Showing High Success Rates in Advanced Melanoma

Immunotherapy /

Results from a Phase 1/2 study show that mRNA-4359, an experimental cancer vaccine, can greatly improve the effectiveness of pembrolizumab (Keytruda) in treating advanced melanoma. In a small group of patients, the combination achieved an 83% response rate and a 92% disease control rate. Patients responded quickly, with tumor shrinkage seen in about six weeks,

mRNA-4359 Boosts Keytruda Response, Showing High Success Rates in Advanced Melanoma Read More »

Novel “Molecular Glue” Drug NST-628 Shows Strong Results in Hard-to-Treat Melanoma and Brain Tumors

Targeted Therapy /

Data shows that NST-628, a new “molecular glue” drug targeting the RAF/MEK pathway, may offer a promising treatment for patients with NRAS and BRAF class II/III mutant melanoma, who currently have few targeted therapy options. In an early phase clinical trial involving heavily pretreated patients, NST-628 showed strong anti-cancer activity. In melanoma patients, it achieved

Novel “Molecular Glue” Drug NST-628 Shows Strong Results in Hard-to-Treat Melanoma and Brain Tumors Read More »

ctDNA-Guided Strategy Shows Promise for Early Detection and Prevention of Head and Neck Cancer Recurrence

Precision Medicine /

Results from the phase 2 MERIDIAN trial show that circulating tumor DNA (ctDNA) can help detect and guide treatment of residual disease in patients with locally advanced head and neck squamous cell carcinoma. Researchers used the RaDaR assay, a personalized blood test, to monitor patients after treatment. The test showed very high accuracy, with positive

ctDNA-Guided Strategy Shows Promise for Early Detection and Prevention of Head and Neck Cancer Recurrence Read More »

Tebentafusp Shows Long-Term Survival Benefit in Metastatic Uveal Melanoma, 5-Year Study Confirms

Treatment /

Five-year results from a phase 3 study show that tebentafusp-tebn significantly improves survival in patients with HLA-A*02:01–positive metastatic uveal melanoma. Patients treated with tebentafusp lived a median of 21.6 months, compared with 16.9 months for those receiving standard therapies such as pembrolizumab, ipilimumab, or dacarbazine. At five years, 16% of patients in the tebentafusp group were

Tebentafusp Shows Long-Term Survival Benefit in Metastatic Uveal Melanoma, 5-Year Study Confirms Read More »

China Approves Belantamab Combination, Showing Major Survival Gains in Multiple Myeloma

Drug Approvals /

National Medical Products Administration has approved belantamab mafodotin with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least one prior therapy. The approval is based on the DREAMM-7 trial, where the combination significantly outperformed a standard daratumumab-based regimen. It extended progression-free survival to 36.6 months versus 13.4 months and reduced

China Approves Belantamab Combination, Showing Major Survival Gains in Multiple Myeloma Read More »

HOXD13 Protein Found to Drive Melanoma Growth and Immune Evasion

Research Advances /

Researchers have identified a protein called HOXD13 as a key driver of melanoma. The study shows that HOXD13 helps cancer grow in two major ways. First, it promotes tumor growth by triggering angiogenesis, the process of forming new blood vessels. These vessels supply the tumor with oxygen and nutrients, allowing it to expand more quickly.

HOXD13 Protein Found to Drive Melanoma Growth and Immune Evasion Read More »